Elicera Therapeutics Ab Stock Gross Profit
| ELIC Stock | 1.89 0.15 8.62% |
Elicera Therapeutics AB fundamentals help investors to digest information that contributes to Elicera Therapeutics' financial success or failures. It also enables traders to predict the movement of Elicera Stock. The fundamental analysis module provides a way to measure Elicera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elicera Therapeutics stock.
Elicera |
Elicera Therapeutics AB Company Gross Profit Analysis
Elicera Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Elicera Therapeutics Gross Profit | 587 |
Most of Elicera Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elicera Therapeutics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Elicera Therapeutics AB reported 587 of gross profit. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The gross profit for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Elicera Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (23.30) % | |||
| Current Valuation | 42.8 M | |||
| Shares Outstanding | 19.78 M | |||
| Shares Owned By Insiders | 62.87 % | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 106.48 X | |||
| Revenue | 587 | |||
| Gross Profit | 587 | |||
| EBITDA | (13.11 M) | |||
| Net Income | (13.12 M) | |||
| Book Value Per Share | 1.85 X | |||
| Cash Flow From Operations | (14.29 M) | |||
| Earnings Per Share | (0.86) X | |||
| Market Capitalization | 78.53 M | |||
| Total Asset | 54.74 M | |||
| Net Asset | 54.74 M |
About Elicera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elicera Therapeutics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elicera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elicera Therapeutics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elicera Stock Analysis
When running Elicera Therapeutics' price analysis, check to measure Elicera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicera Therapeutics is operating at the current time. Most of Elicera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicera Therapeutics' price. Additionally, you may evaluate how the addition of Elicera Therapeutics to your portfolios can decrease your overall portfolio volatility.